These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 23142635)

  • 21. Nanoparticle formulations in pulmonary drug delivery.
    Bailey MM; Berkland CJ
    Med Res Rev; 2009 Jan; 29(1):196-212. PubMed ID: 18958847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects.
    Rogueda PG; Traini D
    Expert Opin Drug Deliv; 2007 Nov; 4(6):595-606. PubMed ID: 17970663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of comparative performance of orally inhaled drug products in view of the classical bioequivalence paradigms: an analysis of the current scientific and regulatory dilemmas of inhaler evaluation.
    Horhota ST
    J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):408-13. PubMed ID: 25237840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of disposable inhalers in pulmonary drug delivery.
    de Boer AH; Hagedoorn P
    Expert Opin Drug Deliv; 2015 Jan; 12(1):143-57. PubMed ID: 25374325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dry powder inhalers: an overview.
    Atkins PJ
    Respir Care; 2005 Oct; 50(10):1304-12; discussion 1312. PubMed ID: 16185366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do all dry powder inhalers show the same pharmaceutical performance?
    Taylor A; Gustafsson P
    Int J Clin Pract Suppl; 2005 Dec; (149):7-12. PubMed ID: 16279997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical perspectives on pulmonary systemic and macromolecular delivery.
    Scheuch G; Kohlhaeufl MJ; Brand P; Siekmeier R
    Adv Drug Deliv Rev; 2006 Oct; 58(9-10):996-1008. PubMed ID: 16996638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Formation, characterization, and fate of inhaled drug nanoparticles.
    Zhang J; Wu L; Chan HK; Watanabe W
    Adv Drug Deliv Rev; 2011 May; 63(6):441-55. PubMed ID: 21118707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces.
    Zhou QT; Morton DA
    Adv Drug Deliv Rev; 2012 Mar; 64(3):275-84. PubMed ID: 21782866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New developments in dry powder pulmonary vaccine delivery.
    Sou T; Meeusen EN; de Veer M; Morton DA; Kaminskas LM; McIntosh MP
    Trends Biotechnol; 2011 Apr; 29(4):191-8. PubMed ID: 21255854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing the performance of two dry powder inhalers in preschool children using an idealized pediatric upper airway model.
    Below A; Bickmann D; Breitkreutz J
    Int J Pharm; 2013 Feb; 444(1-2):169-74. PubMed ID: 23333708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Present Situation and Future Progress of Inhaled Lung Cancer Therapy: Necessity of Inhaled Formulations with Drug Delivery Functions.
    Okuda T; Okamoto H
    Chem Pharm Bull (Tokyo); 2020; 68(7):589-602. PubMed ID: 32611996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Buccal bioadhesive drug delivery--a promising option for orally less efficient drugs.
    Sudhakar Y; Kuotsu K; Bandyopadhyay AK
    J Control Release; 2006 Aug; 114(1):15-40. PubMed ID: 16828915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhaling medicines: delivering drugs to the body through the lungs.
    Patton JS; Byron PR
    Nat Rev Drug Discov; 2007 Jan; 6(1):67-74. PubMed ID: 17195033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of inhalable formulations of anti-inflammatory drugs to potentially treat smoke inhalation injury in burn victims.
    Thai A; Xiao J; Ammit AJ; Rohanizadeh R
    Int J Pharm; 2010 Apr; 389(1-2):41-52. PubMed ID: 20080165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhalation aspects of therapeutic aerosols.
    Leach CL
    Toxicol Pathol; 2007 Jan; 35(1):23-6. PubMed ID: 17325969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery.
    Sakagami M
    Adv Drug Deliv Rev; 2006 Oct; 58(9-10):1030-60. PubMed ID: 17010473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations.
    Hein S; Bur M; Schaefer UF; Lehr CM
    Eur J Pharm Biopharm; 2011 Jan; 77(1):132-8. PubMed ID: 20951200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pulmonary drug delivery: medicines for inhalation.
    Henning A; Hein S; Schneider M; Bur M; Lehr CM
    Handb Exp Pharmacol; 2010; (197):171-92. PubMed ID: 20217530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.